In view of the reported neuroprotective effect of SGLT-2 inhibitors in patients with Alzheimer’s disease, it is strongly believed that the considerable potential of this group of drugs still remains undiscovered, and it will remain a hot scientific topic for a long time to come. The gene discussed is SLC5A2; the disease is early-onset autosomal dominant Alzheimer disease.